Aquestive Therapeutics AQST 深 沪
等待开盘 12-20 09:30:00 美东时间
5.805
-0.005
-0.09%
华盛通- 最 高5.9265
- 今 开5.84
- 成交量 149.03万股
- 最 低 5.775
- 昨 收 5.81
- 总市值 7.02亿
- 52周最高 7.55
- 市盈率 静 --
- 换手率 1.23%
- 52周最低 2.12
- 委 比 7.32%
- 总股本 1.21亿
- 历史最高 20.696
- 量 比 0.74
- 振 幅 2.61%
- 历史最低 0.618
- 每 手 1
- 风险率 1.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Aquestive Therapeutics announced its participation in the Piper Sandler 37th Annual Healthcare Conference, where its management team will discuss Anaphylm™ (dibutepinephrine) sublingual film and meet with investors. The fireside chat with David Amsellem will be webcast and available for 30 days on investors.aquestive.com.
11-24 12:00
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Piper Sandler Maintains Overweight on Aquestive Therapeutics, Raises Price Target to $8
Piper Sandler analyst David Amsellem maintains Aquestive Therapeutics (NASDAQ:AQST) with a Overweight and raises the price target from $5 to $8.
11-07 20:54
Aquestive Therapeutics Advances Anaphylm Towards FDA Approval
Aquestive Therapeutics ( ($AQST) ) has provided an announcement. Aquestive Ther...
11-07 05:57
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
Aquestive Therapeutics announced key leadership changes to support the FDA-approved launch of Anaphylm™ and expand its pipeline. Matthew Davis, M.D., joins as Chief Development Officer, Gary Slatko, M.D., M.B.A., becomes interim Chief Medical Officer, and Peter Boyd, M.B.A., is promoted to Chief People Officer. These strategic moves aim to accelerate product development and commercialization efforts, particularly for Anaphylm™, a first-of-its-kin...
11-04 12:00
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting
Aquestive Therapeutics announced that multiple presentations on its investigational product Anaphylm™ (dibutepinephrine) sublingual film for severe allergic reactions, including anaphylaxis, will be featured at the 2025 ACAAI Annual Meeting in Orlando, FL. Presentations include a Phase 1 evaluation in pediatric patients and posters on pharmacokinetics and unmet needs in anaphylaxis care. Anaphylm, if approved, would be the first oral epinephrine ...
10-30 11:00
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
Aquestive gains after new patent wins for Anaphylm
Shares of Aquestive Therapeutics (NASDAQ:AQST) rose on Wednesday after the company announced that the U.S. regulators had issued two new patents covering its allergy therapy Anaphylm, which is current...
10-09 00:43
